Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Coya Therapeutics, Inc.NASDAQ: COYA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 98.9%

Gross margin was 98.9% in Q1 FY2026, up 2020.8 pp from a year earlier. On a trailing-twelve-month basis it was 99.8%, up 378.1 pp year over year.

Context

  • Gross margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.9%-1.1 pp QoQ
Last fiscal yearDec 2025
99.7%+333.5 pp YoY
LTMMar 2026
99.8%+378.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2020.8 pp——
1 year+333.5 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.7%
Year-over-year change
+333.5pp

Gross Margin vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's LTM Mar 2026 gross margin of 99.8% is the highest of the 7 companies compared; the peer median is 35.3%.
  • Its year-over-year change of +378.1 pp is the highest of 6, against a peer median of -0.5 pp.
COYA Competitors Peer median
Gross Margin for COYA and competitors
Company Period LTM level YoY 3-year change
COYACoya Therapeutics, Inc.LTM Mar 202699.8% +378.1 pp—
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
WHWKWhitehawk Therapeutics IncFY202589.4% +197.4 pp+212.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ORMPOramed Pharmaceuticals Inc.FY20250.7% —-99.4 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
CLNNClene Inc.LTM Mar 2026-182.1% -260.9 pp-16.0 pp
IMMXImmix Biopharma, Inc.FY2025— ——
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding COYA) 35.3%-0.5 pp-10.1 pp

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006M3.55M7.95M
Cost of Revenue04.41M5.5M11.87M27.36K
Gross Profit0(4.41M)500.68K(8.31M)7.92M
Gross Margin——8.3%-233.9%99.7%
Research & Development2.54M4.94M6.04M11.89M16.73M
Selling, General & Admin2.31M4.85M7.83M8.89M11.45M
Operating Expenses4.87M5.4M8.4M8.94M28.18M
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
EBITDA(4.88M)(9.26M)(7.33M)(17.2M)(21.2M)
EBITDA Margin——-122.2%-483.9%-266.8%
Operating Income(4.87M)(9.81M)(7.9M)(17.25M)(20.27M)
Operating Margin——-131.7%-485.4%-255.0%
Interest Income00000
Interest Expense00000
Other Income / Expenses(21.48K)(2.43M)639.37K1.65M(957.4K)
Income Before Tax(4.89M)(12.24M)(7.26M)(15.6M)(21.22M)
Pre-Tax Margin——-121.0%-439.0%-267.1%
Income Tax Expense00723.85K(720.29K)3.09K
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Net Margin——-133.1%-418.7%-267.1%
EPS (Basic)(0.74)(1.23)(0.79)(0.98)(1.27)
EPS (Diluted)(0.74)(1.23)(0.79)(0.98)(1.27)
Weighted Avg Shares6.6M9.95M10.16M15.24M16.73M
Weighted Avg Shares (Diluted)6.6M9.95M10.16M15.24M16.73M

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.